Drug Profile
Research programme: monoclonal antibodies - ElsaLys Biotech
Alternative Names: anti-CD115 monoclonal antibodies - Transgene; ELB-041; TG 3003Latest Information Update: 11 May 2020
Price :
$50
*
At a glance
- Originator Transgene
- Developer ElsaLys Biotech; Transgene
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dendritic cell stimulants; Immunostimulants; Macrophage colony-stimulating factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Solid tumours
Most Recent Events
- 07 May 2020 ElsaLys Biotech has been acquired by Mediolanum
- 28 Jul 2018 No recent reports of development identified for preclinical development in Inflammation in France
- 28 Jul 2018 No recent reports of development identified for preclinical development in Solid-tumours in France